BIOLASE Inc. [NASDAQ: BIOL] jumped around 0.1 points on Monday, while shares priced at $1.01 at the close of the session, up 11.33%. The company report on February 24, 2021 that BIOLASE To Participate In H.C. Wainwright Investor Conference.
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced that John Beaver, President and Chief Executive Officer, will be providing an overview of the Company, as well as recent progress and achievements at the H.C. Wainwright Global Life Sciences Investor Conference, which is being held virtually March 9 – 10, 2021.
The conference will feature virtual one-on-one meetings with the BIOLASE executives and institutional investors are invited to request meeting times at email@example.com or through their H.C. Wainwright representative. The formal, pre-recorded, presentation will be available in the investor relations section of BIOLASE’s website at www.biolase.com.
BIOLASE Inc. stock is now 142.38% up from its year-to-date (YTD) trading value. BIOL Stock saw the intraday high of $1.04 and lowest of $0.9302 per share. The company’s 52-week high price is 1.51, which means current price is +165.79% above from all time high which was touched on 01/26/21.
Compared to the average trading volume of 36.26M shares, BIOL reached a trading volume of 9534517 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about BIOLASE Inc. [BIOL]?
The Benchmark Company have made an estimate for BIOLASE Inc. shares, keeping their opinion on the stock as Speculative Buy, with their previous recommendation back on June 19, 2019. While these analysts kept the previous recommendation, Singular Research raised their target price to Buy. The new note on the price target was released on April 25, 2017, representing the official price target for BIOLASE Inc. stock. Previously, the target price had yet another drop from $4 to $2.50, while WallachBeth kept a Hold rating on BIOL stock. On November 12, 2013, analysts decreased their price target for BIOL shares from 3.50 to 2.75.
The Average True Range (ATR) for BIOLASE Inc. is set at 0.15, with the Price to Sales ratio for BIOL stock in the period of the last 12 months amounting to 6.11. The Price to Book ratio for the last quarter was 5.94, with the Price to Cash per share for the same quarter was set at 0.13.
How has BIOL stock performed recently?
BIOLASE Inc. [BIOL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.72. With this latest performance, BIOL shares dropped by -14.41% in over the last four-week period, additionally plugging by 215.72% over the last 6 months – not to mention a rise of 56.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIOL stock in for the last two-week period is set at 48.22, with the RSI for the last a single of trading hit 44.49, and the three-weeks RSI is set at 51.33 for BIOLASE Inc. [BIOL]. The present Moving Average for the last 50 days of trading for this stock 0.8753, while it was recorded at 0.9644 for the last single week of trading, and 0.4961 for the last 200 days.
BIOLASE Inc. [BIOL]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BIOLASE Inc. [BIOL] shares currently have an operating margin of -41.33 and a Gross Margin at +37.80. BIOLASE Inc.’s Net Margin is presently recorded at -47.24.
Return on Total Capital for BIOL is now -77.99, given the latest momentum, and Return on Invested Capital for the company is -135.93. Return on Equity for this stock declined to -231.42, with Return on Assets sitting at -49.57. When it comes to the capital structure of this company, BIOLASE Inc. [BIOL] has a Total Debt to Total Equity ratio set at 317.64. Additionally, BIOL Total Debt to Total Capital is recorded at 76.06, with Total Debt to Total Assets ending up at 42.09. Long-Term Debt to Equity for the company is recorded at 0.80, with the Long-Term Debt to Total Capital now at 0.02.
Reflecting on the efficiency of the workforce at the company, BIOLASE Inc. [BIOL] managed to generate an average of -$113,726 per employee. Receivables Turnover for the company is 3.80 with a Total Asset Turnover recorded at a value of 1.05.BIOLASE Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.70.
Earnings analysis for BIOLASE Inc. [BIOL]
With the latest financial reports released by the company, BIOLASE Inc. posted -0.05/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BIOL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BIOLASE Inc. go to 20.00%.
Insider trade positions for BIOLASE Inc. [BIOL]
There are presently around $7 million, or 11.70% of BIOL stock, in the hands of institutional investors. The top three institutional holders of BIOL stocks are: ORACLE INVESTMENT MANAGEMENT INC with ownership of 1,739,100, which is approximately 0% of the company’s market cap and around 11.08% of the total institutional ownership; VANGUARD GROUP INC, holding 1,287,859 shares of the stock with an approximate value of $1.3 million in BIOL stocks shares; and PERKINS CAPITAL MANAGEMENT INC, currently with $1.23 million in BIOL stock with ownership of nearly 9.473% of the company’s market capitalization.
Positions in BIOLASE Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 22 institutional holders increased their position in BIOLASE Inc. [NASDAQ:BIOL] by around 2,994,185 shares. Additionally, 15 investors decreased positions by around 754,598 shares, while 8 investors held positions by with 3,654,932 shares. The mentioned changes placed institutional holdings at 7,403,715 shares, according to the latest SEC report filing. BIOL stock had 12 new institutional investments in for a total of 1,252,523 shares, while 10 institutional investors sold positions of 309,320 shares during the same period.